Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
EWING, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals, Inc., a pharmaceutical company developing new and more effective therapies to treat cancer, today announced that patients have been enrolled in an investigator-initiated clinical study evaluating CPX-351 (cytarabine:daunorubicin) Liposome Injection in patients with untreated high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), excluding acute promyelocytic leukemia, at high risk of treatment-related mortality.
Help employers find you! Check out all the jobs and post your resume.
